Canadian dermatology today., Journal Year: 2024, Volume and Issue: unknown
Published: Oct. 2, 2024
The 49th annual Society of Pediatric Dermatology (SPD) meeting was a tremendous success, attracting over 650 attendees, the highest number ever recorded. 3-day conference featured wide range new developments and tips tricks from experts in field.
Language: Английский
Therapeutic Advances in Respiratory Disease, Journal Year: 2025, Volume and Issue: 19
Published: March 1, 2025
In this review, we discuss the risks and adverse effects reported for current Food Drug Association (FDA)-approved biologics used in management of asthma, including omalizumab, benralizumab, dupilumab, mepolizumab, reslizumab, tezepelumab. Our review focuses on risk hypersensitivity reactions, infection, malignancy. Where relevant, have included information regarding cardiovascular disease eosinophilia, specific vaccine use among patients receiving above biologics. We also currently available data context pregnancy. goal is to provide a comprehensive resource providers utilizing these agents, so that they may adequately counsel about therapy identify events if occur.
Language: Английский
Citations
1
Australasian Journal of Dermatology, Journal Year: 2025, Volume and Issue: unknown
Published: March 24, 2025
ABSTRACT Vaccination plays a critical role in protecting against infectious diseases, particularly those with compromised immune systems. While traditional recommendations advise live attenuated vaccination patients undergoing most biologic therapies due to the potential risk of serious infections (vaccine‐related disease caused by unchecked replication vaccine microorganism), emerging evidence and expert opinion suggest vaccines may be safely effectively administered appropriate precautions when using certain medications such as dupilumab apremilast. This systematic review evaluates administration receiving these drugs. A search MEDLINE Embase identified 12 relevant publications, including 2 case series, 3 clinical trials, 7 consensus statements, recommendations, or guidelines. The findings that, circumstances, on precautions. Data apremilast remain limited. Current emphasise shared decision‐making between clinicians patients, considering individual factors. Further is needed establish definitive guidelines therapies.
Language: Английский
Citations
0
Immunology and Allergy Clinics of North America, Journal Year: 2024, Volume and Issue: 44(4), P. 577 - 594
Published: Sept. 2, 2024
Language: Английский
Citations
1
Annals of Allergy Asthma & Immunology, Journal Year: 2024, Volume and Issue: 133(3), P. 234 - 235
Published: July 3, 2024
Language: Английский
Citations
1
Brazilian Journal of Implantology and Health Sciences, Journal Year: 2024, Volume and Issue: 6(8), P. 535 - 545
Published: Aug. 4, 2024
Introdução: A esofagite eosinofílica tem crescido nos últimos anos. Seus sintomas são incapacitantes e trazem prejuízos na qualidade de vida seus portadores. O tratamento convencional falha em muitos casos. imunobiológico dupilumabe se apresenta como alternativa no dessa doença, por meio do bloqueio da atividade Interleucina IL-4 IL-13. Metodologia: Realizou-se uma pesquisa bibliográfica nas plataformas Scielo, Biblioteca Virtual Saúde PubMed. No total, foram identificadas 1268 publicações, com os descritores “esofagite eosinofílica” “dupilumabe”. Após avaliação metodológica, 22 publicações entre 2019 2024 português, espanhol inglês incluídas. Resultados Discussão: foi capaz reduzir as contagens eosinófilos esofágicos melhorar significativamente a histologia esôfago todas apresentações doença. tipo fibroestenótico, medicação conseguiu remissão 100% dos casos estudados. Ademais, apresentou resultados excelentes quando utilizado portadores outras patologias atópicas concomitantes. Em alguns estudos, visualizada capacidade melhoria funcionalidade esôfago. alívio registrado maioria mas não houve unanimidade. Conclusão: representa um importante aliado refratária à medicações primeira linha. Entranto, seu alto custo recente incorporação ao acervo terapêutico doença constituem desafios serem superados. É necessário realização novos principalmente longo prazo, sobre eficácia droga, dose duração necessárias.
Citations
0
Current Dermatology Reports, Journal Year: 2024, Volume and Issue: unknown
Published: Sept. 25, 2024
Language: Английский
Citations
0
Canadian dermatology today., Journal Year: 2024, Volume and Issue: unknown
Published: Oct. 2, 2024
The 49th annual Society of Pediatric Dermatology (SPD) meeting was a tremendous success, attracting over 650 attendees, the highest number ever recorded. 3-day conference featured wide range new developments and tips tricks from experts in field.
Language: Английский
Citations
0